Clinical Intelligence

NIH to join multi-center trial of new tuberculosis vaccine

Tuesday, February 7, 2012 07:34 AM

The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), has joined a phase II proof-of-concept clinical trial of a tuberculosis (TB) vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell.

More... »

Study links coffee, genetics and Parkinson's disease prevention

Monday, February 6, 2012 02:30 PM

A recent study co-authored by Evergreen Healthcare neurologist Dr. Pinky Agarwal finds good news for coffee drinkers: consuming caffeinated coffee may significantly reduce the risk of Parkinson's disease in some individuals depending on their genetics, according to research recently published by the Public Library of Science.

More... »

Inherited risk factors for childhood leukemia more common in Hispanic patients

Monday, February 6, 2012 02:19 PM

Hispanic children are more likely than those from other racial and ethnic backgrounds to be diagnosed with acute lymphoblastic leukemia (ALL) and are more likely to die of their disease, found a study conducted by the Children’s Oncology Group and St Jude Children’s Hospital.

More... »

Henry Ford Hospital first in U.S. to start trial in aggressive brain tumors

Monday, February 6, 2012 02:12 PM

Henry Ford Hospital's Hermelin Brain Tumor Center is the first U.S. hospital to start a new clinical trial for Toca 511 & Toca FC, a combination therapy under investigation for high-grade glioma (HGG), a fast growing, brain cancer that often recurs even after surgery, radiation treatment and chemotherapy.

More... »

Bayer initiates expanded access program for radium-223 chloride

Monday, February 6, 2012 02:11 PM

The FDA has approved of Bayer Healthcare proceeding with its expanded access program to provide the investigational drug radium-223 chloride to patients diagnosed with castration-resistant prostate cancer (CRPC) and hormone-refractory prostate cancer (HRPC) with symptomatic bone metastases.

More... »

Alize licenses Asparec therapy for treatment of leukemia

Monday, February 6, 2012 02:08 PM

Alize Pharma II, a drug development company focused on oncology and metabolism and part of the Alize Pharma group, has signed a license agreement with EUSA Pharma for Asparec, a new L-asparaginase product currently in phase I clinical development for the treatment of acute lymphoblastic leukemia.

More... »

FDA approves Kalydeco to treat rare form of cystic fibrosis

Friday, February 3, 2012 01:46 PM

The FDA has approved Kalydeco (ivacaftor), manufactured by Vertex Pharmaceuticals, for the treatment of a rare form of cystic fibrosis in patients ages six and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.

More... »

FDA removes partial hold on Idenix HCV nucleotide inhibitor

Friday, February 3, 2012 01:43 PM

The FDA has lifted the partial clinical hold on Idenix Pharmaceutical’s IDX184, a hepatitis C virus (HCV) nucleotide inhibitor. The action allows Idenix to continue its 12-week phase IIb study evaluating the drug in combination with pegylated interferon and ribavirin (PegIFN/RBV).

More... »

The CenterWatch Monthly, February 2012

Friday, February 3, 2012 12:01 PM

Anticipating the rise of virtual drug development

More... »

FDA approves Gleevec for rare gastrointestinal cancer

Thursday, February 2, 2012 08:32 AM

The FDA has granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST).

More... »